Prediabetes, Type-2 Diabetes
Conditions
Brief summary
This study examined whether dietary-induced reductions in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in peripheral blood mononuclear cells (PBMC) and plasma affected metabolic profiles in PBMCs and plasma.
Detailed description
Eighty nonobese patients (aged 40-70 years) with prediabetes or newly diagnosed type-2 diabetes were randomly assigned to a control group (normal diet with refined rice) or a whole-grain group (replacement of refined rice with whole-grains and legumes). This dietary intervention replaced approximately 7% of carbohydrate-derived energy with approximately 4% of protein-derived energy and approximately 3% of fat-derived energy.
Interventions
DIETARY_SUPPLEMENTDietary intervention-refined rice
Subjects in the control group maintained the usual refined-rice diet.
DIETARY_SUPPLEMENTDietary intervention-whole grains and legumes
Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* subjects who had IFG (100≤ fasting glucose \<126 mg/dL) * or newly diagnosed type-2 diabetes (fasting glucose ≥126 mg/dL)
Exclusion criteria
* current and/or past history of cardiovascular disease including angina * liver or kidney dysfunction * thyroid or pituitary disease * pregnancy or lactation * taking medications or supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lp-PLA2 Activity in Plasma | Change from baseline in Lp-PLA2 at 12 weeks |
| Lp-PLA2 Activity in PBMC | Change from baseline in Lp-PLA2 at 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| PBMC metabolites | Change in L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0) |
Other
| Measure | Time frame |
|---|---|
| LDL particle size | Changes from baseline in LDL particle size at 12 weeks |
Countries
South Korea
Outcome results
None listed